Global Vunakizumab Market Strategic Research Report

Scope of the Report

The global Vunakizumab market size is predicted to grow from US$ 24.46 million in 2025 to US$ 181 million in 2032; it is expected to grow at a CAGR of 9.1% from 2026 to 2032.

Vunakizumab is a humanized anti‑IL‑17A monoclonal antibody independently developed by Hengrui Medicine. It can specifically bind to Interleukin‑17A (IL‑17A), block its interaction with receptors, inhibit inflammatory signaling pathways, and reduce inflammation in the skin, joints and other tissues. It is mainly used for the treatment of psoriasis, ankylosing spondylitis, psoriatic arthritis and other autoimmune diseases, characterized by high affinity, long half‑life, long dosing interval and good safety.In 2025, global vunakizumab production reached approximately 1.2 million vials.

Vunakizumab is a Class 1 domestic innovative drug independently developed by Hengrui Medicine and one of the first anti-IL-17A monoclonal antibodies approved in China. Since its launch, it has rapidly become an important participant in the therapeutic market for autoimmune diseases. With the advantages of high affinity, low immunogenicity, rapid onset and convenient administration, the drug has broken the long-term monopoly of imported IL-17A inhibitors and provided a domestic alternative for patients with psoriasis, ankylosing spondylitis and other diseases. Driven by three core factors, namely medical insurance coverage, expanded indications and optimized pricing, its market penetration has been continuously improved, making it a core growth product in the field of domestic autoimmunity. In terms of competitive landscape, vunakizumab and selicilizumab from Chuangxiang Jintai constitute the first echelon of domestic IL-17A inhibitors, forming a competition pattern of "import-dominated, domestic catching-up" with imported products from Novartis, Eli Lilly and other companies. In the future, relying on Hengrui's commercialization capacity, medical insurance volume expansion effect and potential indication expansion (such as psoriatic arthritis and rheumatoid arthritis), vunakizumab is expected to further expand its market share and promote domestic substitution and price penetration in the domestic autoimmune disease treatment market.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Vunakizumab market?

What factors are driving Vunakizumab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Vunakizumab market opportunities vary by end market size?

How does Vunakizumab break out by Type, by Application?

This report presents a comprehensive overview of the global Vunakizumab market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 120 mg / 1 ml
• 240 mg / 2 ml

Segment by Production Technology

• Innovator
• Generic

Segment by Antibody Type

• Monoclonal Antibody
• Polyclonal Antibody

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Moderate to Severe Plaque Psoriasis
• Ankylosing Spondylitis
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Vunakizumab market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Moderate to Severe Plaque Psoriasis, Ankylosing Spondylitis, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact